ArticleAnnals of hematology2026
Myelofibrosis and anemia: a German claims data analysis to describe treatment sequencing, survival outcomes, and healthcare resource utilization.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia presents a challenge in the management of myelofibrosis (MF). This symptom may be present at diagnosis or develop soon after, and around half of patients with MF require red blood cell transfusions within the first year. Progression to being transfusion dependent (TD) negatively affects prognosis and quality of life. This retrospective cohort study examined treatment sequencing from MF diagnosis, and overall survival (OS) and healthcare resource utilization (HCRU) from diagnosis and by transfusion status in newly diagnosed patients with MF in Germany. Data from 2010 to 2022 were collected from the AOK PLUS statutory health insurance fund database. Transfusion status was determined during a 180-day landmark period following first anemia treatment; patients were transfusion independent (TI) if they had received no transfusion, TD if they received ≥ 3 transfusions within 12 weeks, and transfusion requiring (TR) if they received transfusions but did not meet TD criteria during the landmark period. Of 555 patients assessed for treatment sequencing, only 41.8% received MF therapies (Janus kinase [JAK] inhibitors, peginterferon alpha-2a, immunomodulators, hydroxycarbamide, allogeneic hematopoietic stem cell transplantation), while 69.0% received anemia-directed interventions (59.8% being blood transfusions). Among patients receiving treatment for anemia (n = 233), transfusion need was associated with shorter median OS (TD: 14.9, TR: 33.3, and TI: 74.3 months after the landmark period) and higher HCRU burden. This study documented high clinical and economic burden of anemia in patients with MF within Germany, particularly among TD patients, highlighting the need for novel treatments providing better prevention of anemia in MF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.